Alivus Life Sciences Limited (NSE:ALIVUS)

Market Cap	115.91B
Revenue (ttm)	24.00B
Net Income (ttm)	4.96B
Shares Out	122.68M
EPS (ttm)	40.32
PE Ratio	23.43
Forward PE	21.41
Dividend	5.00 (0.53%)
Ex-Dividend Date	Sep 1, 2025

Volume	49,092
Average Volume	102,498
Open	947.40
Previous Close	941.70
Day's Range	929.90 - 957.40
52-Week Range	850.00 - 1,251.00
Beta	0.13
RSI	39.64
Earnings Date	Oct 31, 2025

About Alivus Life Sciences

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. The company offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestina...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 2,203
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ALIVUS

Financial Performance

In 2024, Alivus Life Sciences's revenue was 23.87 billion, an increase of 4.54% compared to the previous year's 22.83 billion. Earnings were 4.86 billion, an increase of 3.13%.